Cytelabs Specialized Oncopathology Service Expands into South Indian Hospitals

Cytelabs, an independent and specialist oncopathology cancer diagnostic services provider, plans to spread its services to hospitals and patients throughout South India. Cytelabs, which was launched in 2020 by Cytecare Cancer Hospital, gives surgeons and patients with simple access to high-quality cancer diagnostic services across 65 partnered institutions in Karnataka, Andhra Pradesh, and Telangana. Given the enormous demand, the diagnostic services will be expanded to other states in the near future. Recognizing the scarcity of super-specialized oncopathology in India, Cytelabs was founded with the goal of extending the extraordinary oncopathological expertise available at Cytecare to oncologists, oncosurgeons, and patients outside of the Bengaluru hospital.

"What distinguishes Cytelabs from other diagnostic centers is the presence of highly trained oncopathologists who ensure effective and quick turnaround time at reasonable prices." Cytelabs' experience enables them to provide unrivaled precision and speed, providing cancer surgeons with solid diagnoses to guide their treatment decisions. “We recognize the importance of making our excellent oncopathological services accessible beyond Cytecare. With Cytelabs, we can now cater to the needs of external surgeons, ensuring accurate diagnoses and effective treatment for their patients, thereby advancing cancer diagnostics and treatment on a larger scale. We believe that accurate tissue diagnosis is the fundamental right of all patients, regardless of their location,” she added. Suresh Ramu, CEO & co-founder, Cytecare Cancer Hospitals, said, “We recognize the importance of making our excellent oncopathological services accessible beyond Cytecare. Cytelabs utilizes advanced technologies and techniques to conduct oncopathological testing. The lab also performs specialized tests, such as immunohistochemistry (IHC), integral to cancer diagnosis, using the automated Ventana platform for both diagnostic and prognostic purposes. This focused expertise allows Cytelabs to deliver precise oncopathological services that greatly contribute to improved patient outcomes.